이벤트

모두 보기

    AACR 2023: RenNano® Mice: A Heavy-Chain-Only Antibody Platform for the Generation of Nanobody Therapeutics

    April 19, 2023
    ~에 공유:
    Conclusions

    RenNano® mice contain all human V,D, and J genes in situ with a modified murine constant region designed to generate HCAbs in vivo.

    RenNano® mice mount immune responses in response to multiple antigens.

    RenNano®-derived HCAbs exhibit diversity in germline gene usage and CDR3 length, and demonstrate high affinity and favorable developability characteristics.

    RenNano®-derived HCAbs are functional in vitro.

    RenNano® is a robust and powerful platform to discover HCAb/nanobodies for various therapeutic applications.

    The audio is muted. Click to unmute.